Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2024

Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal or bone metastases in the Phase II VISION trial (#243)

Stephanie Gasking 1 , Niels Reinmuth 2 , Julien Mazieres 3 , Sanjay Popat 4 , Luis Paz-Ares 5 , Emma Hook 6 , Anthony Hatswell 7 , Soetkin Vlassak 8 , Andreas Johne 9 , Helene Vioix 10 , Paul Paik 11
  1. Merck Healthcare Pty. Ltd., Macquarie Park, Australia, an affiliate of Merck KGaA
  2. Asklepios Clinics Munich-Gauting, Department of Thoracic Oncology, Gauting, Germany
  3. CHU de Toulouse, Université Paul Sabatier, Toulouse, France
  4. The Royal Marsden Hospital, London, United Kingdom
  5. Hospital Universitario 12 de Octubre, Madrid, Spain
  6. Delta Hat, Nottingham, United Kingdom
  7. Delta Hat, Nottingham, United Kingdom
  8. Merck N.V.-S.A., Overijse, Belgium, an affiliate of Merck KGaA
  9. Merck Healthcare KGaA, Darmstadt, Germany
  10. Global Evidence and Value Development, Merck Healthcare KGaA, Darmstadt, Germany
  11. Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, United States of America

Aims: Tepotinib, a highly selective MET inhibitor, showed robust and durable activity in patients with METex14 skipping NSCLC in the VISION trial (NCT02864992). Systemic and intracranial activity was seen in patients with brain metastases. We analyzed HRQoL in patients with brain, liver, adrenal or bone metastases.

Methods: Eligible patients (including patients with brain metastases if asymptomatic or neurologically stable on a stable steroid dose) received oral tepotinib 500 mg (450 mg active moiety) once daily. HRQoL was assessed at baseline and during follow-up using the EORTC QLQ-C30 Global Health Score (GHS), EQ-5D-5L visual analog scale (VAS), and EORTC QLQ-LC13 cough, dyspnea, and chest pain scores. Subgroup analyses evaluated patients with brain, liver, adrenal or bone metastases at baseline per independent review (data cut-off: November 20, 2022). Mean change from baseline across all visits was evaluated by linear mixed model regression in patients with baseline and ≥1 post-baseline score.

Results: Of 313 enrolled patients, change from baseline in HRQoL was evaluable in 52 patients with brain, 56 with liver, 54 with adrenal, and 86 with bone metastases. At baseline, among all the evaluable patients, mean ± standard error (SE) EORTC QLQ-C30 GHS was worst in patients with bone metastases (49.90 ± 2.03), followed by patients with adrenal (51.85 ± 2.51), liver (58.33 ± 2.77), or brain metastases (59.94 ± 2.53). A similar pattern was observed for baseline EQ-5D-5L VAS (bone: 60.42 ± 1.94; adrenal: 63.06 ± 2.45; liver: 65.30 ± 2.46; brain: 66.75 ± 2.57). During tepotinib treatment, all patients with metastases maintained HRQoL and improved their symptoms, especially the patients with brain metastases.

Conclusion: In the VISION trial in METex14 skipping NSCLC, patients with brain, liver, adrenal or bone metastases maintained overall HRQoL during tepotinib treatment, with trends for improvement in cough, consistent with results for the overall population.